US 12,186,344 B2
Cell populations having immunoregulatory activity, method for isolation and uses
Dirk Büscher, Madrid (ES); Manuel Angel González de la Peña, Madrid (ES); and Mario Delgado Mora, Granada (ES)
Assigned to Tigenix, S.A.U., Madrid (ES); and Consejo Superior de Investigaciones Cientificas, Madrid (ES)
Filed by TIGENIX, S.A.U., Madrid (ES); and CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, Madrid (ES)
Filed on Apr. 13, 2022, as Appl. No. 17/659,157.
Application 14/464,147 is a division of application No. 12/067,708, abandoned, previously published as PCT/EP2006/009244, filed on Sep. 22, 2006.
Application 17/659,157 is a continuation of application No. 15/581,801, filed on Apr. 28, 2017, abandoned.
Application 15/581,801 is a continuation of application No. 14/464,147, filed on Aug. 20, 2014, granted, now 9,943,550, issued on Apr. 17, 2018.
Claims priority of application No. 05077186 (EP), filed on Sep. 23, 2005.
Prior Publication US 2022/0313742 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/35 (2015.01); A61K 35/12 (2015.01); A61K 39/00 (2006.01); C12N 5/0775 (2010.01); C12N 5/0783 (2010.01)
CPC A61K 35/35 (2013.01) [A61K 39/0008 (2013.01); A61K 39/001 (2013.01); A61K 39/4611 (2023.05); A61K 39/4621 (2023.05); A61K 39/46433 (2023.05); C12N 5/0636 (2013.01); C12N 5/0637 (2013.01); C12N 5/0667 (2013.01); A61K 2035/122 (2013.01); A61K 2035/124 (2013.01); C12N 2501/24 (2013.01)] 13 Claims
 
1. A method of treating an inflammatory bowel disease in a subject comprising systemically administering to the subject an isolated cell population from adipose tissue that has not been stimulated with interferon-gamma (IFN-γ), wherein the cell population comprises a therapeutically effective amount of cells that express indolamine 2,3-dioxygenase (IDO) when stimulated with IFN-γ, wherein the cells comprised in the cell population have the following characteristics:
(i) the cells when administered do not express the markers CD11b, CD11c, CD14, CD45 and HLAII,
(ii) the cells do not express IDO constitutively,
(iii) the cells have the capacity to be differentiated into at least two cell lineages, and
(iv) the cells are homogeneous.